Giardiasis: Conceptos modernos sobre su control y tratamiento

Thompson, R.C.A.

doi:10.1159/000151270

Cited by 6 publications

(8 citation statements)

References 79 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of probiotic lactobacilli releases a low molecular weight thermosensitive factor that inhibits the proliferation of Giardia trophozoites in in vitro culture. These modern therapeutic strategies justify further investigation which could prove to be more applicable and useful than drugs for the treatment in endemic regions [8,52].…”

Section: Other Controls For Giardiasismentioning

confidence: 99%

Pharmacological Treatment of Giardiasis

Díaz¹

2017

Current Topics in Giardiasis

View full text Add to dashboard Cite

Giardiasis is a disease caused for a myoflagellate protozoan known as Giardia duodenalis, of which varieties have been described and whose morphological characteristics are identical to other species such as G. lamblia and G. intestinalis; considered for various authors as the same species, this protozoan parasites several domestic species including man, but has important relevance in the canine and feline species, due to their zoonotic potential. In recent years, the number of cases of canine and feline giardiasis has increased, not only because it is treated of a cosmopolitan parasite, which is closely related to unsanitary conditions, but also because the conventional treatments for its control and eradication have shown resistance phenomena. It is for this reason and being a parasite of potential zoonotic risk that at present pharmacological tests have been developed in the search for new alternatives for the treatment of giardiasis, especially in the canine and feline species as mentioned earlier.

show abstract

Section: Other Controls For Giardiasismentioning

confidence: 99%

Pharmacological Treatment of Giardiasis

Díaz¹

2017

Current Topics in Giardiasis

View full text Add to dashboard Cite

show abstract

“…Giardia duodenalis is a species complex including eight morphologically indistinguishable genotypes (A, B, C, D, E, F, G, H) with different host specificity [ Table-1] [1,2,[37][38][39]. Recently, some investigators have proposed species-specific names for the different genotypes of G. duodenalis [ Table-1] [40,41].…”

Section: Molecular Epidemiology Of Giardiamentioning

confidence: 99%

Giardia duodenalis: NEW INSIGHTS ON AN ANCIENT PARASITE

NB¹,

Ja²

2013

Int J Parasitol Res

View full text Add to dashboard Cite

“…There are several pharmaceutical agents that are used in the treatment of the giardiasis including metronidazole [ 6 ], albendazole, tinidazole, and nitazoxanide [ 7 ]; some of them are administered by one dose and others (as metronidazole) need several doses along the day for two or three days. In refractory cases by resistance or reinfection the combination of two or more drugs can be necessary [ 8 , 9 ]. All chemical agents produce collateral effects like nausea, metallic taste, yellow pigmentation of the skin, hepatic damage, inefficacy in the treatment, and resistance [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Antigiardial Effect of Kramecyne in Experimental Giardiasis

Eligio-García

Pontifez-Pablo

Pérez-Gutiérrez³

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

A variety of drugs are used in giardiasis treatment with different levels of efficiency, presence of side effects, and even formation of resistant strains, so that it is important to search new only-one-dose treatments with high efficiency and less side effects. Kramecyne, an anti-inflammatory compound isolated from methanolic extract of Krameria cytisoides, does not present toxicity, even at doses of 5,000 mg/kg. The objective was to determine the antigiardial effect of kramecyne over Giardia intestinalis in vitro and in vivo and analyze the expression of genes ERK1, ERK2, and AK on kramecyne treated trophozoites by Real Time Polymerase Chain Reaction (RTPCR). The median lethal dose (LD50) was 40 μg/mL and no morphological changes were observed by staining with blue trypan and light microscopy; experimental gerbil infection was eliminated with 320 μg/Kg of weight. After treatment there were no differences between intestines from treated and untreated gerbils. Kramecyne did not have significant effect over ERK1 and AK, but there are differences in ERK2 expression (p = 0.04). Results show antigiardial activity of kramecyne; however the mode of action is still unclear and the evaluation of ultrastructural damage and expressed proteins is an alternative of study to understand the action mechanism.

show abstract

Giardiasis: Conceptos modernos sobre su control y tratamiento

Cited by 6 publications

References 79 publications

Pharmacological Treatment of Giardiasis

Pharmacological Treatment of Giardiasis

Giardia duodenalis: NEW INSIGHTS ON AN ANCIENT PARASITE

Antigiardial Effect of Kramecyne in Experimental Giardiasis

Contact Info

Product

Resources

About